Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D08NLQ
|
||||
| Former ID |
DCL000867
|
||||
| Drug Name |
Licarbazepine
|
||||
| Synonyms |
GP 47779; GP-47779; (-)-10,11-Dihydro-10-hydroxy-5H-dibenz(b,f)azepine-5-carboxamide; 10,11-Dihydro-10-hydroxy-5H-dibenz(b,f)azepine-5-carboxamide; 10,11-Dihydro-10-hydroxycarbamazepine; 10-HYDROXY-CARBAMAZEPINE; 10-Hydroxy-10,11-dihydro-5H-dibenz(b,f)azepine-5-carboxamide; 10-Hydroxy-10,11-dihydrocarbamazepine; 10-Hydroxycarbamazepine; 10-Hydroxycarbazepine; 10-OH-Carbazepine; 5-hydroxy-5,6-dihydrobenzo[b][1]benzazepine-11-carboxamide
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Bipolar disorder [ICD9: 296.0, 296.1, 296.4, 296.5, 296.6, 296.7, 296.8, 300; ICD10:F31, F40-F42] | Discontinued in Phase 3 | [536295] | ||
| Company |
Novartis
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C15H14N2O2
|
||||
| Canonical SMILES |
C1C(C2=CC=CC=C2N(C3=CC=CC=C31)C(=O)N)O
|
||||
| InChI |
1S/C15H14N2O2/c16-15(19)17-12-7-3-1-5-10(12)9-14(18)11-6-2-4-8-13(11)17/h1-8,14,18H,9H2,(H2,16,19)
|
||||
| InChIKey |
BMPDWHIDQYTSHX-UHFFFAOYSA-N
|
||||
| CAS Number |
CAS 29331-92-8
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
9696, 7784957, 10236459, 15122329, 29296358, 49961418, 53786979, 57338774, 74832374, 91612621, 103096889, 103292732, 104179204, 104396686, 117569774, 123109974, 125823413, 127537463, 135070112, 137128961, 137237041, 139113422, 162261761, 162312777, 162831436, 163418503, 163850052, 164840168, 172866983, 179293331, 223395621, 223438646, 226745918, 237439165, 249582091, 249857730, 250071337, 250217218, 252070881, 252157593, 252237691, 252325768, 252419301, 252474827
|
||||
| Target and Pathway | |||||
| Target(s) | Sodium channel | Target Info | Blocker | [536295] | |
| KEGG Pathway | Dopaminergic synapse | ||||
| Reactome | Interaction between L1 and Ankyrins | ||||
| References | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.